PEAK6’s Viking Therapeutics VKTX Stock Holding History

PEAK6’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$1.32M	–	3517
2025 Q2	$1.32M	Hold	50,000	–	–	﹤0.01%	1659
2025 Q1	$1.21M	Buy	+50,000	New	+$1.58M	﹤0.01%	1668

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PEAK6's VKTX Position: Q3 2025 in Review

PEAK6 sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 31,194 shares — an estimated $827K sold.

PEAK6 first reported a position in VKTX in Q4 2024 and held it in 3 quarters. The position peaked at $827K in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

PEAK6 reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 31,194 Viking Therapeutics shares in Q3 2025, an estimated $827K.
PEAK6 first reported a position in Viking Therapeutics in Q4 2024 and held it in 3 quarters.
PEAK6's Viking Therapeutics position peaked at $827K in Q2 2025.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.